Processa Pharmaceuticals Stock Analysis

Processa Stock Analysis Notes

The company has price-to-book ratio of 0.95. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Processa Pharmaceuticals recorded a loss per share of 28.75. The entity last dividend was issued on the 23rd of December 2019. The firm had 1:25 split on the 17th of December 2025. Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. Processa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. To find out more about Processa Pharmaceuticals contact the company at 443 776 3133 or learn more at https://www.processapharmaceuticals.com.

Processa Pharmaceuticals Investment Alerts

Processa Largest EPS Surprises

View All Earnings Estimates

Processa Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Processa Stock Institutional Investors

Note, although Processa Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Processa Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.12 M.

Processa Profitablity

Management Efficiency

Processa Pharmaceuticals has return on total asset (ROA) of (1.2994) % which means that it has lost $1.2994 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7074) %, meaning that it created substantial loss on money invested by shareholders. Processa Pharmaceuticals' management efficiency ratios could be used to measure how well Processa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of February 10, 2026, Return On Tangible Assets is expected to decline to -3.47. The current year's Return On Capital Employed is expected to grow to -7.76. At present, Processa Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 9.7 M, whereas Total Assets are forecasted to decline to about 3.5 M.

Technical Drivers

As of the 10th of February, Processa Pharmaceuticals holds the Variance of 334.56, coefficient of variation of (2,496), and Risk Adjusted Performance of (0.02). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Processa Pharmaceuticals, as well as the relationship between them.

Processa Pharmaceuticals Price Movement Analysis

Processa Pharmaceuticals Insider Trading Activities

Processa Pharmaceuticals Outstanding Bonds

Processa Pharmaceuticals Predictive Daily Indicators

Processa Pharmaceuticals Forecast Models

Processa Pharmaceuticals' time-series forecasting models are one of many Processa Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Processa Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Processa Pharmaceuticals Bond Ratings

Processa Pharmaceuticals financial ratings play a critical role in determining how much Processa Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Processa Pharmaceuticals' borrowing costs.

Processa Pharmaceuticals Debt to Cash Allocation

Processa Pharmaceuticals currently holds 73.51 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Processa Pharmaceuticals has a current ratio of 8.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Processa Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Processa Pharmaceuticals Total Assets Over Time

Processa Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Processa Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Processa Pharmaceuticals Debt Ratio

2.49

It appears most of the Processa Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Processa Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Processa Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Processa Pharmaceuticals Corporate Bonds Issued

Processa Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Processa Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Processa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Processa Pharmaceuticals. By using and applying Processa Stock analysis, traders can create a robust methodology for identifying Processa entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Processa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Processa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Processa Pharmaceuticals stock analysis indicators help investors evaluate how Processa Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Processa Pharmaceuticals shares will generate the highest return on investment. By understating and applying Processa Pharmaceuticals stock analysis, traders can identify Processa Pharmaceuticals position entry and exit signals to maximize returns.

When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.